Abstract:The N-ethoxycarbonylmorpholine moiety was evaluated as a novel prodrug moiety for carboxylic acid containing drugs represented by diclofenac (1). Compound 2, the N-ethoxycarbonylmorpholine ester of diclofenac was synthesized and evaluated as a potential prodrug. The stability of the synthesized prodrug was evaluated in solutions of pH 1 and 7.4, and in plasma. The ester’s half lives were found to be 8 h, 47 h and 21 min in pH 1, pH 7.4 and plasma, respectively. Equimolar doses of diclofenac sodium and its synt… Show more
“…The prodrug synthesized N-ethoxycarbonylmorpholine ester of diclofenac (Fig. 107 ) [ 93 ]. The stability of the prodrug was evaluated in buffer solution and in plasma.…”
Intoroduction:Prodrug approach deals with chemical biotransformation or enzymatic conversion or involves inactive or less active bio-reversible derivatives of active drug molecules. They have to pass through enzymatic or chemical biotransformation before eliciting their pharmacological action.Methods & Materials:The two different pharmacophores combine to give synergistic activity or may help in targeting the active drug to its target. Prodrug super seeds the problems of prodrug designing, for example solubility enhancement, bioavailability enhancement, chemical stability improvement, presystemic metabolism, site specific delivery, toxicity masking, improving patient acceptance, or eradicating undesirable adverse effects.Results:As an outcome the search for a prodrug or mutual prodrug with reduced toxicity has continued during recent years. This present review emphasizes the common help to revamp physiochemical, pharmaceutical and therapeutic effectiveness of drugs.Conclusion:This gives the researcher a common platform where they can find prodrugs of commonly used NSAIDs to overcome the gastrointestinal toxicity (irritation, ulcergenocity and bleeding).
“…The prodrug synthesized N-ethoxycarbonylmorpholine ester of diclofenac (Fig. 107 ) [ 93 ]. The stability of the prodrug was evaluated in buffer solution and in plasma.…”
Intoroduction:Prodrug approach deals with chemical biotransformation or enzymatic conversion or involves inactive or less active bio-reversible derivatives of active drug molecules. They have to pass through enzymatic or chemical biotransformation before eliciting their pharmacological action.Methods & Materials:The two different pharmacophores combine to give synergistic activity or may help in targeting the active drug to its target. Prodrug super seeds the problems of prodrug designing, for example solubility enhancement, bioavailability enhancement, chemical stability improvement, presystemic metabolism, site specific delivery, toxicity masking, improving patient acceptance, or eradicating undesirable adverse effects.Results:As an outcome the search for a prodrug or mutual prodrug with reduced toxicity has continued during recent years. This present review emphasizes the common help to revamp physiochemical, pharmaceutical and therapeutic effectiveness of drugs.Conclusion:This gives the researcher a common platform where they can find prodrugs of commonly used NSAIDs to overcome the gastrointestinal toxicity (irritation, ulcergenocity and bleeding).
“…We believe that this is the first attempt that compares the antipyretic effectiveness of the rectal forms of Paracetamol and Diclofenac. Diclofenac is rapidly absorbed in those parts of the gastrointestinal tract that have pH values higher than five ( 23 ). Paracetamol is also highly absorbed under alkaline conditions; however, its absorption is less dependent on the environmental pH ( 24 , 25 ).…”
BackgroundFever is the most common complaint in pediatric medicine and its treatment is
recommended in some situations. Paracetamol is the most common antipyretic drug, which
has serious side effects such as toxicity along with its positive effects. Diclofenac is
one of the strongest non-steroidal anti-inflammatory (NSAID) drugs, which has received
little attention as an antipyretic drug.ObjectivesThis study was designed to compare the antipyretic effectiveness of the rectal form of
Paracetamol and Diclofenac.Patients and MethodsThis double-blind controlled clinical trial was conducted on 80 children aged six
months to six years old. One group was treated with rectal Paracetamol suppositories at
15 mg/kg dose and the other group received Diclofenac at 1 mg/kg by rectal
administration (n = 40). Rectal temperature was measured before and one hour after the
intervention. Temperature changes in the two groups were compared.ResultsThe average rectal temperature in the Paracetamol group was 39.6 ± 1.13°C,
and 39.82 ± 1.07°C in the Diclofenac group (P = 0.37). The average rectal
temperature, one hour after the intervention, in the Paracetamol and the Diclofenac
group was 38.39 ± 0.89°C and 38.95 ± 1.09°C, respectively (P =
0.02). Average temperature changes were 0.65 ± 0.17°C in the Paracetamol group
and 1.73 ± 0.69°C in the Diclofenac group (P < 0.001).ConclusionsIn the first one hour, Diclofenac suppository is able to control the fever more
efficient than Paracetamol suppositories.
“…90). 304 The prodrug exhibited good intrinsic chemical stability, with t 1/2 values of 8 h and 47 h at pH 1.0 and 7.4, respectively, but degraded more readily in human plasma, with a t 1/2 of 21 min. This indicated that the prodrug would have sufficient stability in the GI tract to ensure intact absorption, while undergoing rapid activation in the plasma by esterases to release the parent.…”
Section: Design Of Prodrugs That Mitigate Toxicity For Non-oncology I...mentioning
Recent tactical applications of prodrugs as effective tools in drug discovery and development to resolve issues associated with drug delivery of lead and drug candidates are reviewed as a reflection of the approval of 53 prodrugs during 2012–2022.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.